Evaluating the effects of ivacaftor exposure on Staphylococcus aureus small colony variant development and antibiotic tolerance
Gretchen E Bollar, Kendall M Shaffer, Johnathan D Keith, Ashley M Oden, Alexander E Dowell, Kevin J Ryan, Edward P Acosta, Jennifer S Guimbellot, Megan R Kiedrowski, Susan E Birket · 2024
Read Evaluating the effects of ivacaftor exposure on Staphylococcus aureus small colony variant development and antibiotic tolerance by Gretchen E Bollar, Kendall M Shaffer, Johnathan D Keith, Ashley M Oden, Alexander E Dowell, Kevin J Ryan, Edward P Acosta, Jennifer S Guimbellot, Megan R Kiedrowski, Susan E Birket (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11630538.txt.
Description
Gretchen Bollar leads a team of ten authors in 2024 in asking whether a cystic fibrosis drug can push a stubborn lung bacterium into a harder-to-kill form. Ivacaftor helps people with cystic fibrosis and also fights Staphylococcus aureus directly, yet the bacterium often lingers in their lungs despite treatment.
The worry is small colony variants, slow-growing forms of the bacterium tied to long-lasting infection. The team dosed rats carrying the human cystic fibrosis gene defect with the drug for a week and measured levels in blood and lung tissue. Their tests check whether normal drug exposure nudges the bacteria toward this persistent state.
Catalog record
| CREATOR | Gretchen E Bollar, Kendall M Shaffer, Johnathan D Keith, Ashley M Oden, Alexander E Dowell, Kevin J Ryan, Edward P Acosta, Jennifer S Guimbellot, Megan R Kiedrowski, Susan E Birket |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 37 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |